-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
news
newsRecently, Glaxo started a phase 0 clinical trial of GBM, the PARP inhibitor niraparib (trade name Zejula) acquired from Tesaro
Drug source analysis
Drug source analysisEveryone knows that there are usually three phases of clinical trials before drugs are marketed, but before the emergence of the accelerated approval system, only phase three clinical trials are the real big test
AbbVie's PARP inhibitor Veliparib became the first drug to take a crab, and completed the first phase 0 clinical trial of a tumor drug.
There are special reasons why PARP inhibitors have returned to the old industry and started phase 0 clinical trials, which are importantly different from the peripheral drug concentration and activity observed by Veliparib
In terms of molecular mechanism, PARP inhibitors inhibit DNA repair, and the two GBM pillars of TMZ and radiotherapy induce DNA damage to form a pinch.